4.6 Article

Experimental evaluation of icodextrin delivery as pressurized aerosol (PIPAC): Antiadhesive and cytotoxic effects

期刊

EJSO
卷 47, 期 6, 页码 1434-1440

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ejso.2021.02.012

关键词

Intraperitoneal chemotherapy; Icodextrin; Adhesions; Cisplatin; Doxorubicin; Cancer; Pressurized IntraPeritoneal aerosol chemotherapy; PIPAC

资金

  1. University of Tubingen
  2. Capnomed GmbH

向作者/读者索取更多资源

The study demonstrates the feasibility of using Icodextrin solution as a carrier for pressurized intraperitoneal aerosol chemotherapy with Cisplatin and Doxorubicin. Icodextrin remains stable after aerosolization, significantly affects the adhesion of gastric cancer cells, and does not impair the cytotoxic effects of the chemotherapeutic drugs.
Background: Icodextrin (IDX) is an antiadhesive polymer that can be used as a carrier solution for intraperitoneal (IP) delivery of chemotherapeutic drugs. Methods: We investigated the suitability of IDX solution as a carrier of Cisplatin and Doxorubicin for delivery as pressurized intraperitoneal aerosol chemotherapy (PIPAC). We examined the sprayability of IDX, the aerosol characteristics, the stability of the molecule after aerosolization, the effects of IDX on the adhesion of MKN45 human gastric cancer cells, the synergistic effect of aerosolized IDX with Cisplatin and Doxorubicin, and the chemical stability of IDX, Cisplatin, and Doxorubicin in combination. Results: Delivery of IDX as PIPAC is feasible with no particular restrictions. The median droplet size of 35.7 mm did not change at increasing concentrations. IDX withstood the shear forces applied by the nebulizer and remained stable after aerosolization (ANOVA, p = 0.97). IDX did not impair the cytotoxic effects of Cisplatin and Doxorubicin (ns). IDX had a significant antiadhesive impact alone (p < 0.03) and in combination with Cisplatin and Doxorubicin (p < 0.02). IDX as a carrier for Cisplatin and Doxorubicin remained stable at 4 degrees C for three months and did not cause degradation of those two substances. Conclusion: The proposed combination takes advantage of the antiadhesive properties of IDX, the cytotoxic effect of Cisplatin and Doxorubicin, and an advanced drug delivery system. (C) 2021 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据